CABA

Cabaletta Bio, Inc. is an innovative clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, specializing in advanced T-cell therapies designed to address B-cell-mediated autoimmune diseases. With a strong pipeline supported by proprietary research and a deep commitment to enhancing patient outcomes, Cabaletta is poised to revolutionize treatment approaches within this therapeutic area. The company’s expertise in immunotherapy, combined with its patient-focused initiatives, highlights its potential for substantial contributions to the biopharmaceutical landscape, making it a compelling proposition for institutional investors seeking exposure to cutting-edge healthcare solutions.